Keyphrases
Phase II Trial
38%
Metastatic Breast Cancer
30%
Breast Cancer
29%
Breast Cancer Patients
28%
Trastuzumab
27%
Triple-negative Breast Cancer
26%
Lapatinib
26%
Phase II Study
20%
Dual HER2 Blockade
20%
Trastuzumab Emtansine
19%
Paclitaxel
19%
Clinical Data
18%
Neoadjuvant
17%
Reporting System
17%
Invasive Micropapillary Carcinoma of the Breast
17%
Breast Imaging
17%
Preclinical Data
17%
Leptomeningeal Metastasis
17%
Data Systems
17%
HER2-positive Breast Cancer
17%
Targeted Therapy
15%
Invasive Micropapillary Carcinoma
14%
Estrogen Receptor-positive Breast Cancer
13%
Capecitabine
13%
Patients with Breast Cancer
13%
Residual Cancer Burden
13%
Taxanes
12%
Pembrolizumab
12%
Lexicon
11%
Overall Survival
10%
Docetaxel
10%
Ixabepilone
10%
Pertuzumab
10%
Nab-paclitaxel
10%
Mammalian Target of Rapamycin (mTOR)
10%
National Cancer Database
9%
Breast Cancer Treatment
9%
Clinical Factors
9%
Anthracyclines
9%
HER2-targeted Therapy
9%
Breast Cancer Research
9%
DNA Repair Pathways
8%
Monitoring Disease Progression
8%
Chloroquine
8%
TAK-228
8%
Ovarian Suppression
8%
Virus Gene
8%
Adjuvant Therapy
8%
Post-diagnostic Support
8%
Treatment Modalities
8%
Medicine and Dentistry
Breast Cancer
100%
Triple Negative Breast Cancer
34%
Malignant Neoplasm
32%
Breast Imaging - Reporting And Data System
22%
Biopsy Technique
22%
Overall Survival
20%
Neoplasm
19%
Metastatic Carcinoma
19%
Cancer Risk
19%
Hormone Receptor
18%
Micropapillary
17%
Carcinoma
16%
Diseases
16%
Targeted Therapy
15%
Estrogen Receptor Positive Breast Cancer
13%
Radiation Therapy
13%
Metastatic Breast Cancer
13%
Clinical Trial
12%
Health Care
12%
Cancer
12%
Prognostic Factor
11%
Language Processing
11%
Mammography
11%
N(g) Methylarginine
11%
Leuprorelin
10%
Tamoxifen
10%
Breast Carcinoma
10%
Cytotoxic T-Cell
10%
Risk Stratification
10%
Germ Cell
9%
Adjuvant Therapy
9%
Nitric Oxide Synthase Inhibitor
9%
Neoadjuvant Chemotherapy
9%
BRCA1
8%
Mammalian Target of Rapamycin
8%
Melanoma
8%
Phase II Trials
8%
Emergency Care
8%
Immune Checkpoint Blockade
8%
T Cell
8%
Palbociclib
8%
Topotecan
8%
DNA Repair
8%
Cell-Free DNA
8%
Cancer Rehabilitation
8%
Specific Tumor
8%
Olaparib
8%
Disease Management
8%
T-Helper Cell
8%
Cerebrospinal Fluid
8%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
37%
Malignant Neoplasm
29%
Phase II Trials
27%
Neoplasm
26%
Triple Negative Breast Cancer
26%
Chemotherapy
25%
Metastatic Breast Cancer
24%
Taxane
21%
Paclitaxel
20%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
17%
Trastuzumab
17%
Lapatinib
17%
Estrogen Receptor Positive Breast Cancer
13%
Clinical Trial
12%
Leuprorelin
11%
Tamoxifen
11%
Overall Survival
11%
N(g) Methylarginine
11%
Anthracycline
11%
Docetaxel
10%
Hormone Receptor
9%
Nitric Oxide Synthase Inhibitor
9%
Palbociclib
8%
Capecitabine
8%
CD8 Antigen
8%
Melanoma
8%
Olaparib
8%
Trastuzumab Emtansine
8%
Pertuzumab
8%
First-Line Chemotherapy
8%
Inducible Nitric Oxide Synthase
8%
Chloroquine
8%
Disease Free Survival
8%
Treatment Group
8%
Bevacizumab
8%
Dermatological Agent
8%
Progression Free Survival
6%
Placebo
6%
Patient History of Chemotherapy
5%
Aromatase Inhibitor
5%
Adverse Event
5%
Gonadorelin Agonist
5%
